Navigation Links
TREK to Introduce New In Vitro Diagnostic and Research-Use-Only Susceptibility Products at American Society for Microbiology General Meeting, Booth 1301

- Company receives clearance to add voriconazole to its YeastOne(R) susceptibility plate for in vitro diagnostics; plate now includes four FDA-cleared antifungal agents

- New Research-Use-Only Sensititre(R) Xtra Gram Negative MIC Plate incorporates 21 antimicrobics, including colistin and polymixin B

CLEVELAND, May 14 /PRNewswire/ -- TREK Diagnostic Systems, a Magellan Biosciences company and premier provider of diagnostic systems and susceptibility products for microbiology labs, will introduce two new susceptibility plates next week at the American Society for Microbiology (ASM) general meeting. TREK's YeastOne susceptibility plate for in vitro diagnostics and research-use-only Sensititre Xtra Gram Negative MIC plate both build on the company's leading platform of Sensititre susceptibility products, which are used widely by physicians and researchers as they work to address the serious and growing problem of drug-resistant infections, and by pharmaceutical companies in their new drug development.

"Susceptibility testing is a critical tool in combating drug resistance," explained James Whelan, president of Magellan's Clinical Diagnostics business. "It is now well known that the widespread and inappropriate use of antibiotics contributes to the creation of 'superbugs' that have become immune to many existing drugs. There has also been a documented increase in recent years of drug-resistant fungal infections, particularly in severely immuno-compromised and/or critically ill patients. The latter is the target of our new YeastOne dried microbroth dilution plate (Part No. YO-2V), which increases reportable compounds and treatment options for clinicians."

Mr. Whelan continued, "Increasingly, clinicians and researchers are relying on combinations of drugs. At TREK, we provide microbiology labs with both the latest FDA-cleared drugs and the widest range of formulations in a platform that improves test methods and reduces costs. The goal of our IVD susceptibility products is to help physicians safely and effectively fight infection without contributing to drug resistance by ensuring that they prescribe the right drug treatment or drug combination to stop microbial growth. YeastOne is the first in vitro diagnostic-labeled susceptibility product that is FDA-cleared for testing Candida species isolates against four commonly prescribed FDA-cleared antifungal agents: voriconazole, fluconazole, 5-flucytosine, and itraconazole. The plate features standard 24-hour incubation, easy-to-read colorimetric endpoints, and on-scale QC ranges, making antifungal susceptibility testing a viable in-house procedure for any size laboratory."

Turning to the company's new Sensititre Xtra Gram Negative MIC Plate (Part No. GNXF), Mr. Whelan said, "Our research-use-only plates help scientists better understand drug resistance. We designed this new Gram negative plate to include the antimicrobics colistin and polymixin B at the request of drug-resistance researchers because of resurgence in the use of these 50-year-old antibiotics to treat multi-drug-resistant infections. The plate incorporates 21 antimicrobic compounds, including doripenem, colistin, polymixin B, doxycycline, minocycline, ertapenem, and imipenem. In the U.S. and Canada, the plate is available for research-use-only, not for use in diagnostic procedures; minocycline, colistin and polymixin B have not been FDA-cleared for IVD use with FDA-approved interpretive criteria. Plates can be read manually and with TREK's Vizion(R) system, or read using the automated ARIS 2X System."

ARIS is part of the company's line of Sensititre Automated Susceptibility and Identification Testing products, designed so labs can test -- on a single cost-effective, LIS-compatible system -- more FDA-cleared antimicrobial drugs than on any other automated platform against the widest range of non-fastidious and fastidious bacteria and yeasts. Sensititre takes the guesswork out of reading susceptibility results and eliminates the need for microbiology labs to use multiple off-line test procedures to obtain accurate susceptibility data. Since Sensititre is the susceptibility platform that pharmaceutical companies use in their drug-development process, TREK has early access to the latest antimicrobial therapies. Sensititre is also the system-of-choice for global surveillance programs, including NARMS (National Antimicrobial Resistance Monitoring System).

The company will also feature at ASM its FDA-cleared Vizion System, which integrates with a lab's information system to eliminate transcription errors. It also adds easy-to-read digital imaging capability, enabling users to share or store images for future reference, training, and decision-making processes. TREK's award-winning VersaTREK(R) Automated Microbial Detection System will also be on view. VersaTREK is the only system that performs four tests on one automated platform: culture for blood, sterile body fluids, and mycobacteria, as well as Mycobacterium tuberculosis (TB) susceptibility testing.

The 109th annual ASM General Meeting will be held May 17-21, 2009, at the Pennsylvania Convention Center in Philadelphia. TREK will exhibit in Booth 1301. TREK will also present a number of poster presentations at the ASM meeting, including the following:

    Monday, May 18, 2009     A Multi-Site Study Comparing an 18-24h
    10:45 am to 12:15 pm     Sensititre(R) Susceptibility System to the
    Presentation: C-015      CLSI Broth Microdilution Method for Oritavancin
    Poster #: 133            Using Fastidious and non-Fastidious Gram-positive

    Monday, May 18, 2009     A Multi-Site Study of the Sensititre(R)
    10:45 am to 12:15 pm     Susceptibility System Compared with the CLSI
    Presentation: C-012      Microdilution Method for MIC Determination of
    Poster #: 136            Gram-Negative and Gram-Positive Organisms vs.

    Monday, May 18, 2009     An Equivalency Study of the Sensititre(R) Dried
    10:45 am to 12:15 pm     MIC System Compared with the CLSI Broth
    Presentation: C-011      Microdilution Reference Method for TR-700 and
    Poster #: 110            Comparator Antimicrobials

    Monday, May 18, 2009     A Retrospective Examination of Mycobacteria
    10:45 am to 12:15 pm     Recovery Rates from the VersaTREK Automated
    Presentation: C-022      Microbial Detection System and the MGIT(R)960
    Poster #: 143

    Monday, May 18, 2009     Resins Do not Adsorb All Antibiotics at Peak
    1 to 2:30 pm             Serum Concentrations, Especially the Newer Beta-
    Presentation: C-048      Lactam Antibiotics
    Poster #: 290

About TREK Diagnostic Systems (

A Magellan Biosciences diagnostics company, TREK is a global manufacturer and distributor of automated systems and consumable products for microbiology-based diagnostic testing designed to improve patient outcomes. Signature product lines include VersaTREK(R), Sensititre(R), Vizion(R), alamarBlue(R), para-JEM(R), YeastOne(R), onSite(R), and TREK Lab Services. TREK is committed to delivering the highest quality products and services to clinical, pharmaceutical, and veterinary diagnostic laboratories worldwide.

SOURCE TREK Diagnostic Systems
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Delta Dental of Illinois Introduces Smile Smart For Your Health
2. Highmark Blue Cross Blue Shield Introduces New Health Plan Comparison Tool for Consumers
3. Highmark Blue Shield Introduces New Health Plan Comparison Tool for Consumers
4. Sentillion Introduces Affordable Next Generation Healthcare Single Sign-On Solution Called expreSSO(TM)
5. GladRags Introduces the Moon Cup - An Environmentally-Sound and Safe Alternative to Disposable Feminine Hygiene Products!
6. Triveris Introduces Personal Health Record with Built-in Health Advisor
7. Verizon Introduces Broadband Video Call Center Link for Deaf or Hard-of-Hearing Customers in Mid-Atlantic Region
8. National CPR/AED Awareness Week Introduced in Congress
9. Mecklenburg EMS Introduces Most-Advanced Situational Training in America for Emergency Medical Personnel
10. Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis
11. Sentillion Introduces Affordable Next Generation Healthcare Single Sign-On Solution Called expreSSO(TM)
Post Your Comments:
(Date:11/25/2015)... , ... November 25, 2015 , ... On November 10, ... States District Court of Connecticut on behalf of a home health care worker who ... current or former home health care workers employed by Humana, Inc., Humana at Home, ...
(Date:11/25/2015)... ... , ... On November 25, 2015, officials of Narconon Arrowhead , the ... of a new cutting edge recovery program that has been 50 years in the ... alcohol-addicted individuals with the purpose to free addicts from the symptoms and negative behaviors ...
(Date:11/25/2015)... ... , ... SCOTTSDALE, AZ) - Today, Dr. Todd C. ... and non-surgical treatments, announced the expansion of his private practice capabilities with the ... Highly trained and nationally recognized for his natural approach, Dr. Todd Hobgood serves ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Today, ... on our nation’s roadways has dropped below 10,000 for the first time since 2011. ... in 2013. , According to data released by the National Highway Traffic Safety Administration ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... of philanthropic seniors, is resulting in a way for homeless people to have ... Schaumburg have launched a new initiative whereby they are repurposing plastic bags into ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... , November 25, 2015 ... due to repeated failure of IVF cycles. After failure ... was totally dejected and had lost all hopes that she would be able ... Indian miracle child conceived after failure of over 15 ... abroad (UK) before they decided to take one last attempt with ...
(Date:11/24/2015)... SAN CARLOS, Calif. , Nov. 24, ... ), a leader in non-invasive genetic testing ... today announced that it will present at ... Conference in New York on Wednesday, December 2, 2015 at 1:00 p.m. ... discuss the Company,s financial results, business activities ...
(Date:11/24/2015)... /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") ... the first patient has been enrolled in ESSA,s Phase ... metastatic castration-resistant prostate cancer ("mCRPC"). the ... the United States and Canada.  ... trial, ESSA intends to demonstrate the safety, tolerability, maximum ...
Breaking Medicine Technology: